Sonic Incytes Medical Corp.

As we hit the #RoadToEurope we’re showcasing the innovators from around the globe who are selected to present at #LSIEurope24. Today we’re showcasing 3 innovators in Canada selected to present at LSI Europe ‘24 in Portugal: 1. Laurent Laferrière — Ditch Labs → Developing a digital platform for the treatment of substance abuse disorders. The platform uses software/device combinations to address the physiological and psychological addiction concurrently. 2. Chris Springate — ARC Medical Inc. → Has developed the only liquid medical device which forms a temporary barrier film to prevent surgical adhesions throughout the entire surgical area. Surgical indications include gynecological & abdominal and orthopedic surgeries – knee, shoulder & hip. 3. Barry Allen — Sonic Incytes Medical Corp. → The company’s Velacur is a portable, handheld ultrasound that integrates machine learning to enhance image guidance, resulting in a confident assessment of liver health in all body types. Scans using the Velacur system can be performed in the physician's office in approximately 5 minutes, producing real-time measurements of liver stiffness and attenuation. We look forward to seeing these innovators take the stage this September 16th - 20th in Portugal. Want to see what other innovators are presenting at LSI Europe ‘24? Head over to our website to see the first 100 innovators selected to present.

INOVAIT Canada member Sonic Incytes Medical Corp. will be represented at #LSIEurope24! CEO Barry Allen will be presenting the company's machine learning-enhanced ultrasound imaging device for liver health in Portugal this September.

Fatty liver disease, encompassing both Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic dysfunction-Associated Steatohepatitis (MASH), is a growing concern globally. By the time symptoms appear, significant liver damage might have already occurred. Early assessment can prevent progression, manage comorbidities and ensure that patients receive tailored treatment. Who Should Be Assessed? Certain risk factors significantly increase the likelihood of developing fatty liver disease. If you have any of the following risk factors, it's important to discuss liver health with your healthcare provider: - Type 2 Diabetes: A significant percentage of people with type 2 diabetes are affected by MASLD, with estimates ranging from 50% to 75%. Managing diabetes effectively is crucial, as high blood sugar levels can exacerbate liver fat accumulation and inflammation. - Obesity: Individuals suffering with obesity are at a higher risk. Current data suggests that up to 70% of people with obesity may have MASLD. - Metabolic Syndrome: This includes conditions like hypertension, dyslipidemia (high triglycerides or low HDL cholesterol), and insulin resistance. - Sedentary Lifestyle: Lack of physical activity is a known risk factor. - Unhealthy Diet: Diets high in sugar, refined carbohydrates, and unhealthy fats contribute to fatty liver disease. - Genetic Predisposition: Family history of liver disease or certain genetic mutations can increase risk. - Polycystic Ovary Syndrome (PCOS): Women with PCOS are at higher risk due to associated insulin resistance and obesity. - Sleep Apnea: This condition is linked with insulin resistance and metabolic syndrome, increasing the risk for MASLD. Read more in today's blog: https://lnkd.in/gXW8t8AX American Association for the Study of Liver Diseases (AASLD)EASL | The Home of Hepatology European Liver Patients' Association - ELPALPI LIVER PATIENTS INTERNATIONAL Global Liver Institute Global NASH Council Echosens E-Scopics Mindray Siemens Healthineers Fibronostics Perspectum Ltd Tawazun Health Surfing MASH American Diabetes Association KNS Canada Inc. Novo Nordisk Inventiva Pharma Eli Lilly and Company Madrigal Pharmaceuticals Jeffrey V. Lazarus Barcelona Institute for Global Health (ISGlobal) Zobair Younossi Scott Isaacs, MD, FACP, FACE

Sharing Zobair Younossi's upcoming poster at the American Diabetes Association conference this week. "Screening for Presence of High-Risk Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) In the U.S. Primary Care Is Cost Effective [Board No. 1043]" Is screening for MASLD by Primary Care Physicians really cost effective? "Results: After 20-years, all 9 screening strategies provided lower cumulative mortality (4.1% to 5.8% reduction), reduction in advanced fibrosis (24.7% to 30.9% reduction) and were cost-effective as compared to no screening [ICERs ranging between $22,119 to $28,778 per QALY gained in T2D, $69,289 to $79,260 in Pre-D, and $69,686 to $80,034 in ≥1-CMR (willingness-to-pay threshold of $100,000 per QALY)]. The cost-effectiveness of screening strategies was consistent with scenario and sensitivity analyses." "Conclusions: Recently published guidelines for high-risk MASLD screening are cost-effective and should be considered in primary care." Echosens, Sonic Incytes Medical Corp., E-Scopics, Mindray, Perspectum Ltd, LiverScan Direct, Tawazun Health, Livera Health, Arizona Liver Health, Siemens Healthineers, Aegle Medical, James M. Paik, LINDA HENRY, Maria Stepanova, Fatema Nader VP Clinical Operations

"This is a moment in the evolution of MASH care that we will look back on in 10-15 years and recognize how everything has changed. Importantly, integrating scans into current and ongoing MASH therapeutic clinical trials has made it easier to introduce new MASH drugs into physician workflows" - This great piece by Kevin Pho, M.D. summarizes the turning point we're at with liver care. #MASH #MASLD #FattyLiverDisease #LiverHealth https://lnkd.in/ge2PGXCU

Today is Global Fatty Liver Day! 🌍 Understanding the risks and getting screened for fatty liver disease is crucial for early detection and prevention. Here’s what you need to know: 💡 Know the Risks: Obesity, diabetes, high cholesterol, and excessive alcohol consumption increase your risk of fatty liver disease. 🔎 Get Screened: Regular check-ups and liver function tests can detect fatty liver disease early, even if you have no symptoms. 🏃♀️ Take Action: If you're at risk, talk to your healthcare provider about getting screened and steps to protect your liver health. Prioritize your liver health today. Early detection can make all the difference. 💚 #KnowTheRisks #GetScreened #LiverHealth#GlobalFattyLiverDay #MASLD #MASH #NAFLD #NASH https://lnkd.in/gZHDUzYH

Studies have shown that noninvasive diagnostic methods for #liverdisease are much better accepted by #patients compared to #liver biopsies. One study found that patient acceptance for noninvasive methods like transient elastography was over 90%, whereas acceptance for liver biopsy was significantly lower due to its invasive nature and associated discomfort. Learn more at: https://lnkd.in/g6KqptdR #FattyLiverDay #ActNowScreenToday #BeyondtheBiopsy #LiverHealth #NASH #MASH #liverhealth #liver

Exciting to see new data and progress on #MASH treatments!

We’re proud to contribute to research that helps drive progress in #NASH / #MASH at this year’s EASL | The Home of Hepatology Annual Congress. We’re excited to meet with the #hepatology community at the event. #EASL2024 #EASLCongress 

We’re at #DDW2024! Visit us at Booth #832 and get your liver scanned with our point of care, AI guided technology. #masld #mash #nafld #nash #fattyliverdisease